Previous 10 | Next 10 |
Acceptance by European Union and other global health authorities of the pivotal, adaptive Phase 2b/3 trial will significantly shorten bexotegrast’s time to Phase 3 data Upsized Oxford Finance debt facility extends cash runway and funds accelerated development through 20...
2024-03-04 09:38:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Positive interim 12-week safety and efficacy data reported from Phase 2a INTEGRIS-PSC trial in patients with PSC Enrollment continues in BEACON-IPF, a Phase 2b trial in patients with IPF SOUTH SAN FRANCISCO, Calif., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasd...
2024-02-11 23:32:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-02-05 08:55:19 ET More on Pliant Therapeutics Pliant Therapeutics: Targeting Idiopathic Pulmonary Fibrosis Pliant Therapeutics GAAP EPS of -$0.70 beats by $0.08 Seeking Alpha’s Quant Rating on Pliant Therapeutics Historical earnings data for Plian...
Bexotegrast (PLN-74809) at 320 mg was well tolerated over 12 weeks of treatment with no drug-related severe or serious adverse events; No safety concerns identified across all dose cohorts Bexotegrast at 320 mg reduced liver fibrosis markers ELF and PRO-C3 and showed improvements in h...
2024-01-03 12:41:31 ET Summary Today, we take a deeper look at Pliant Therapeutics, Inc., which has a promising lead asset and is targeting potentially lucrative indications in the treatment of fibrosis and related diseases. Analyst firms are optimistic about Pliant Therapeutics' ...
SOUTH SAN FRANCISCO, Calif., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced that Bernard Coulie, M.D., Ph.D., President and Chief Executive Officer, is scheduled to present at the 42 nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9,...
SOUTH SAN FRANCISCO, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases, today announced the presentation of preclinical...
Pliant Therapeutics Inc. (PLRX) is expected to report $-0.78 for Q3 2023
News, Short Squeeze, Breakout and More Instantly...
Pliant Therapeutics Inc. Company Name:
PLRX Stock Symbol:
NASDAQ Market:
Pliant Therapeutics Inc. Website:
Bexotegrast at 320 mg was well tolerated up to 40 weeks of treatment with no treatment-related severe or serious adverse events 320 mg cohort demonstrated improvement in liver stiffness by transient elastography at Week 24 compared to placebo Statistically significant ...
2024-06-14 00:10:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
SOUTH SAN FRANCISCO, June 13, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a late-stage biotechnology company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases, today announced the appointment of Steve Krognes to its Boa...